Article info

Download PDFPDF

Extended report
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Authors

  1. Correspondence to Dr Christopher Ritchlin, Allergy, Immunology & Rheumatology Division, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA; Christopher_Ritchlin{at}URMC.Rochester.edu
View Full Text

Citation

Ritchlin C, Rahman P, Kavanaugh A, et al
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Publication history

  • Received September 23, 2013
  • Revised January 3, 2014
  • Accepted January 5, 2014
  • First published January 30, 2014.
Online issue publication 
April 30, 2014

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

  • Lay summary

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.